SCHEMBL2465334

SCHEMBL2465334

Fc1c(C(F)(F)F)ccc2nc(N3CCNCC3)n3ncnc3c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 1/20 0.40
ADRB2 P07550 4/20 0.39
ADRB1 P08588 2/20 0.38
EPHX2 P34913 1/20 0.38
SOS1 Q07889 5/20 0.38
CYP2C19 P33261 1/20 0.38
NCF1 P14598 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PTPN11 Q06124 1/20 0.34
ADRA2A P08913 1/20 0.33
HTR2C P28335 1/20 0.33
AXL P30530 1/20 0.33
HRH1 P35367 1/20 0.33
HTR2B P41595 1/20 0.33
HTR6 P50406 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465670 0.87 HRH4 (0.43) CYP1A2ADRB2CYP2C19KDM4EALDH1A1
SCHEMBL2533033 0.86 SOS1 (0.35) CYP1A2CYP2C9ADRB1SOS1NCF1
Hydrochloric Acid SCHEMBL2466905 0.85 SOS1 (0.35) CYP1A2CYP2C9ADRB1SOS1NCF1
SCHEMBL12225078 0.84 SOS1 (0.41) SOS1
SCHEMBL2533770 0.84 SOS1 (0.39) SOS1HTR3A
SCHEMBL2465329 0.83 MTOR (0.34) KDM4E
SCHEMBL2464899 0.80 HRH4 (0.46)
SCHEMBL12224801 0.78 SOS1 (0.42) CYP1A2CYP2C9ADRB2ADRB1EPHX2
SCHEMBL12224904 0.78 SOS1 (0.42) CYP1A2CYP2C9ADRB2ADRB1EPHX2
SCHEMBL10013931 0.76 ADRB2 (0.50) CYP1A2ADRB2ADRB1SOS1NCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 CYP1A2 2609/4885CYP2C9 2484/4885ADRB2 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.